Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'

UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS

November 11, 2015 9:44 AM EST

(Updated - November 11, 2015 9:49 AM EST)

(correction: price target is $255)

UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More

Valeant Pharma (VRX) to Employ Drug Discounting Strategy in Effort to 'Protect Volume'

November 11, 2015 7:22 AM EST

Valeant Pharma (NYSE: VRX) will be using an old business tactic as it looks to retain customers following recent controversial headlines surrounding the company:... More

Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura

November 11, 2015 7:20 AM EST

Nomura Securities analyst Shibani Malhotra lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $175.00 (from $220.00) but reiterated a Buy rating as her "Conservative Base Case" suggest 109% upside to current levels.

While the call did not address all our outstanding questions; however,... More

Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% Loss

November 10, 2015 2:01 PM EST

Embattled Valeant Pharma (NYSE: VRX) has gone solidly positive territory mid-day after trading down as much as 7.5% earlier. Shares last traded at $85.63, up 0.3%. Upside is related to... More

BMO 'Incrementally Positive' on Valeant (VRX) Following Conf. Call; Still See N-T Headline Risk Affecting Shares

November 10, 2015 10:57 AM EST

BMO Capital is out with commentary on Valeant Pharma (NYSE: VRX) following today's conference call.

Analyst Alex Arfaei said the firm is incrementally positive on Valeant following the event. The analyst believes management provided good commentary about their near-term plans, and status of business operations. The focus now is on the remaining headline risk and execution in 2016.

Arfai sees near-term headline risk on Valeant as medium-to-high until the conclusion of the committee's investigation, at the earliest. The analyst commented, Valeants business is under high... More

Drugmaker Valeant to feel sting of closing controversial pharmacy

November 10, 2015 8:26 AM EST

By Euan Rocha and Rod Nickel

TORONTO/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.

As of last week, Philidor Rx Services has stopped handling insurance claims for drugs and it will cease operations by the end of January, Valeant Chief Executive Officer Mike Pearson told investors and analysts on a conference call on Tuesday.

The call, however,... More

UPDATE: Valeant Pharma (VRX) Sees Negative Q4 Impact from Recent Events; Will Issue New Guidance in Dec.

November 10, 2015 8:08 AM EST

(Updated - November 10, 2015 8:23 AM EST)

(Updated - November 10, 2015 8:17 AM EST)

Valeant Pharma (NYSE: VRX) sees negative impact on dermatology in Q4, according to the company's... More